Close

NeoGenomics (NEO) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook

Go back to NeoGenomics (NEO) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook

BTIG Upgrades Neogenomics (NEO) to Buy

October 27, 2016 7:26 AM EDT

BTIG upgraded Neogenomics (NASDAQ: NEO) from Neutral to Buy with a price target of $10. Analyst Sean Lavin sees a compelling entry point.

"When we downgraded shares at $9, our view was that a fair amount of good news had been priced in easing reimbursement... More